104.54
price down icon0.32%   -0.34
after-market アフターアワーズ: 105.00 0.46 +0.44%
loading
前日終値:
$104.88
開ける:
$104.74
24時間の取引高:
8.07M
Relative Volume:
0.94
時価総額:
$132.77B
収益:
$28.75B
当期純損益:
$480.00M
株価収益率:
282.54
EPS:
0.37
ネットキャッシュフロー:
$10.31B
1週間 パフォーマンス:
+3.10%
1か月 パフォーマンス:
-6.88%
6か月 パフォーマンス:
+19.67%
1年 パフォーマンス:
+56.19%
1日の値動き範囲:
Value
$103.52
$105.75
1週間の範囲:
Value
$100.76
$107.18
52週間の値動き範囲:
Value
$62.07
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
名前
Gilead Sciences Inc
Name
セクター
Healthcare (1151)
Name
電話
(650) 574-3000
Name
住所
333 LAKESIDE DR, FOSTER CITY, CA
Name
職員
17,600
Name
Twitter
@GileadSciences
Name
次回の収益日
2025-02-11
Name
最新のSEC提出書
Name
GILD's Discussions on Twitter

GILD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
104.54 132.77B 28.75B 480.00M 10.31B 0.37
Drug Manufacturers - General icon
LLY
Lilly Eli Co
839.96 677.40B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
JNJ
Johnson Johnson
157.47 371.98B 89.33B 21.81B 18.06B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
172.99 316.82B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
58.08 293.24B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
110.86 216.19B 51.72B 11.94B 13.81B 5.88

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-04 繰り返されました Oppenheimer Outperform
2025-02-18 アップグレード Deutsche Bank Hold → Buy
2025-02-13 アップグレード DZ Bank Hold → Buy
2025-01-10 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-12-10 再開されました BofA Securities Buy
2024-11-15 開始されました Wolfe Research Outperform
2024-11-14 開始されました Citigroup Buy
2024-11-08 ダウングレード Maxim Group Buy → Hold
2024-10-21 アップグレード Leerink Partners Market Perform → Outperform
2024-10-17 開始されました Bernstein Outperform
2024-10-07 アップグレード Wells Fargo Equal Weight → Overweight
2024-07-08 アップグレード Raymond James Mkt Perform → Outperform
2024-05-01 繰り返されました Maxim Group Buy
2024-04-24 アップグレード HSBC Securities Reduce → Hold
2024-02-22 ダウングレード Truist Buy → Hold
2023-11-09 開始されました Deutsche Bank Hold
2023-09-08 アップグレード BofA Securities Neutral → Buy
2023-09-06 開始されました HSBC Securities Reduce
2023-07-24 繰り返されました Barclays Equal Weight
2023-05-16 アップグレード BMO Capital Markets Market Perform → Outperform
2023-04-28 再開されました Piper Sandler Overweight
2023-01-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2022-12-13 再開されました BofA Securities Neutral
2022-12-09 ダウングレード DZ Bank Buy → Hold
2022-10-31 アップグレード Barclays Underweight → Equal Weight
2022-10-28 繰り返されました BMO Capital Markets Market Perform
2022-10-28 繰り返されました Cowen Outperform
2022-10-28 繰り返されました JP Morgan Overweight
2022-10-28 繰り返されました Jefferies Buy
2022-10-28 アップグレード Piper Sandler Neutral → Overweight
2022-10-28 繰り返されました RBC Capital Mkts Outperform
2022-10-28 アップグレード Truist Hold → Buy
2022-10-28 繰り返されました Wells Fargo Equal Weight
2022-10-04 アップグレード JP Morgan Neutral → Overweight
2022-07-13 開始されました Cantor Fitzgerald Neutral
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-02-28 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-02-02 繰り返されました BMO Capital Markets Outperform
2022-02-02 繰り返されました BofA Securities Neutral
2022-02-02 繰り返されました RBC Capital Mkts Outperform
2022-02-02 繰り返されました Truist Hold
2022-02-02 繰り返されました Wells Fargo Equal Weight
2022-01-28 アップグレード Argus Hold → Buy
2022-01-06 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-12-09 再開されました Wells Fargo Equal Weight
2021-12-06 開始されました Goldman Neutral
2021-11-19 アップグレード BMO Capital Markets Market Perform → Outperform
2021-11-19 再開されました Piper Sandler Neutral
2021-10-20 再開されました Cowen Outperform
2021-07-30 繰り返されました BMO Capital Markets Market Perform
2021-07-30 繰り返されました RBC Capital Mkts Outperform
2021-04-01 アップグレード Bernstein Mkt Perform → Outperform
2021-03-30 アップグレード Redburn Neutral → Buy
2021-01-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-01-04 アップグレード Guggenheim Neutral → Buy
2020-11-03 再開されました Morgan Stanley Equal-Weight
2020-10-28 開始されました UBS Neutral
2020-09-30 再開されました Jefferies Buy
2020-09-15 アップグレード Maxim Group Hold → Buy
2020-07-31 繰り返されました Credit Suisse Neutral
2020-07-31 繰り返されました Morgan Stanley Equal-Weight
2020-07-31 繰り返されました Piper Sandler Overweight
2020-07-31 繰り返されました RBC Capital Mkts Outperform
2020-07-31 繰り返されました SunTrust Hold
2020-07-31 繰り返されました Wells Fargo Equal Weight
2020-07-20 アップグレード Credit Suisse Underperform → Neutral
2020-06-03 アップグレード SVB Leerink Mkt Perform → Outperform
2020-05-26 アップグレード SunTrust Sell → Hold
2020-05-01 ダウングレード JP Morgan Overweight → Neutral
2020-05-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-01 ダウングレード SunTrust Hold → Sell
2020-04-27 ダウングレード UBS Buy → Neutral
2020-04-20 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-04-20 ダウングレード Wells Fargo Overweight → Equal Weight
2020-04-17 ダウングレード CFRA Hold → Sell
すべてを表示

Gilead Sciences Inc (GILD) 最新ニュース

pulisher
Apr 17, 2025

BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115 - MarketScreener

Apr 17, 2025
pulisher
Apr 17, 2025

Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating - MarketScreener

Apr 17, 2025
pulisher
Apr 17, 2025

News - Department of Health Abu Dhabi

Apr 17, 2025
pulisher
Apr 17, 2025

DoH Partners with Gilead Sciences to propel healthcare innovation and cell therapy advancement - ZAWYA

Apr 17, 2025
pulisher
Apr 17, 2025

Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell - MarketScreener

Apr 17, 2025
pulisher
Apr 17, 2025

2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around - The Motley Fool

Apr 17, 2025
pulisher
Apr 16, 2025

Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know - MSN

Apr 16, 2025
pulisher
Apr 16, 2025

Gilead Sciences CFO sells $266,000 in stock - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

Gilead Sciences CFO sells $266,000 in stock By Investing.com - Investing.com India

Apr 16, 2025
pulisher
Apr 16, 2025

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program - CSRwire

Apr 16, 2025
pulisher
Apr 16, 2025

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - MSN

Apr 16, 2025
pulisher
Apr 16, 2025

Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now? - Insider Monkey

Apr 16, 2025
pulisher
Apr 15, 2025

11 Most Undervalued Quality Stocks to Buy Now - Insider Monkey

Apr 15, 2025
pulisher
Apr 15, 2025

Lobbying Update: $75,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Nasdaq

Apr 15, 2025
pulisher
Apr 15, 2025

Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 15, 2025
pulisher
Apr 15, 2025

Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price - simplywall.st

Apr 15, 2025
pulisher
Apr 14, 2025

EPO board revives Gilead patent, sends case back for review - MLex

Apr 14, 2025
pulisher
Apr 14, 2025

Gilead patent partially upheld by EPO, Teva and STADA's challenge continues - MLex

Apr 14, 2025
pulisher
Apr 14, 2025

Here's What to Expect From Gilead Sciences’ Next Earnings Report - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

Gilead reprimanded after PMCPA finds conference Wi-Fi sponsorship broke advertising rules - Fierce Pharma

Apr 14, 2025
pulisher
Apr 14, 2025

Here's What To Expect From Gilead Sciences’ Next Earnings Report - Barchart.com

Apr 14, 2025
pulisher
Apr 11, 2025

Gilead Sciences, Trusaic Data Breach Lawsuit Investigation - ClassAction.org

Apr 11, 2025
pulisher
Apr 11, 2025

PatientView Ranks Gilead “Best” at ESG - CSRwire

Apr 11, 2025
pulisher
Apr 11, 2025

Gilead Sciences Inc (GILD) Shares Gap Down to $100.87 on Apr 10 - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Gilead Sciences To Release First Quarter 2025 Financial Results On Thursday, April 24, 2025 - MarketScreener

Apr 10, 2025
pulisher
Apr 10, 2025

Gilead Sciences Announces Q1 Estimated Acquired IPR&D - MarketScreener

Apr 10, 2025
pulisher
Apr 10, 2025

Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 | GILD Stock News - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 - Business Wire

Apr 10, 2025
pulisher
Apr 10, 2025

AI-startup Prezent names Gilead Sciences’ exec to Board - StartUp Beat

Apr 10, 2025
pulisher
Apr 10, 2025

PatientView Ranks Gilead "Best" at ESG - MarketScreener

Apr 10, 2025
pulisher
Apr 10, 2025

Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug - statnews.com

Apr 10, 2025
pulisher
Apr 10, 2025

Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy - MarketScreener

Apr 10, 2025
pulisher
Apr 10, 2025

Manufacturer’s plans for equitable access to twice-yearly PrEP under fire - Aidsmap

Apr 10, 2025
pulisher
Apr 09, 2025

Mich. Panel: Gilead Immune From Recalled COVID Drug Suit - Law360

Apr 09, 2025
pulisher
Apr 09, 2025

Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance

Apr 09, 2025
pulisher
Apr 09, 2025

Gilead, Michigan Hospital Win Appeal Over Tainted Covid-19 Drug - Bloomberg Law News

Apr 09, 2025
pulisher
Apr 09, 2025

Gilead Sciences (GILD) Anticipates Earnings Surprise - GuruFocus

Apr 09, 2025
pulisher
Apr 09, 2025

Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Apr 09, 2025
pulisher
Apr 09, 2025

AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States - Gilead Sciences

Apr 09, 2025
pulisher
Apr 09, 2025

Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections - CSRwire

Apr 09, 2025
pulisher
Apr 09, 2025

Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1 - Insider Monkey

Apr 09, 2025
pulisher
Apr 09, 2025

Weekly CFO Sells Highlight: Adobe Systems, Gilead Sciences and A - GuruFocus

Apr 09, 2025
pulisher
Apr 08, 2025

July 18th Options Now Available For Gilead Sciences (GILD) - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

Gilead Sciences describes new nucleoside prodrugs for viral infections - BioWorld MedTech

Apr 08, 2025
pulisher
Apr 08, 2025

Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.

Apr 08, 2025
pulisher
Apr 07, 2025

In Bay Area, Gilead cuts 149 positions and Roche's diagnostics division lays off 108 - Fierce Pharma

Apr 07, 2025
pulisher
Apr 07, 2025

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? - Nasdaq

Apr 07, 2025
pulisher
Apr 07, 2025

Optimistic Growth Prospects for Gilead Sciences: Buy Rating Backed by HIV and Oncology Advancements - TipRanks

Apr 07, 2025
pulisher
Apr 05, 2025

Gilead Sciences - drugdiscoverytrends.com

Apr 05, 2025

Gilead Sciences Inc (GILD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general SNY
$50.90
price up icon 0.67%
drug_manufacturers_general PFE
$22.14
price up icon 0.45%
$277.29
price down icon 1.89%
drug_manufacturers_general MRK
$78.00
price up icon 2.01%
drug_manufacturers_general NVS
$110.86
price up icon 1.17%
大文字化:     |  ボリューム (24 時間):